Skip to main content
Equibles
VRDN logo

VRDN · Viridian Therapeutics, Inc.\DE · Metrics

Track VRDN — free

Use VRDN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VRDN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$23.01 +0.58 (+2.59%) At close · Oct 21
Russell 2000 member Rebalance outlook locked
Market Cap
$2.59B
Shares
113.29M
Volume · Oct 21 1.92M Avg daily vol (3M) 1.8M

VRDN metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$23.01
Market cap
$2.59B

Price action

20 metrics
Price change (1W)
+23.1%
Price change (30D)
+3.9%
Price change (3M)
+16.9%
Price change (6M)
+57.1%
Price change (YTD)
-27.9%
Price change (1Y)
-6.9%
Trailing year
Price change (5Y)
+35.5%
52-week high
$33.78
52-week low
$13.30
Change from 52-week high
-33.6%
Change from 52-week low
+68.6%
Annualized volatility
72.0%
Annualized volatility (3M)
51.4%
Beta
1.0
RSI (14D)
63.7
Price vs SMA 50
+3.9%
Price vs SMA 200
+1.6%
Avg volume (3M)
1.79M
Relative volume
1.1
Average dollar volume
$37.67M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
113.29M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
37.3×
reciprocal yield 2.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
34.6×
reciprocal yield 2.9%
P / book
3.7
reciprocal yield 26.9%
FCF yield
-13.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-15.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2,213.6×
reciprocal yield 0.0%
EV / revenue historical average (5Y)
1,561.4×
reciprocal yield 0.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-05-05

Profitability

9 metrics
Gross margin
—
Operating margin
-569.7%
Trailing 12 months
Net margin
-544.1%
Gross profit (TTM)
$3.06M
Operating profit (TTM)
−$405.20M
Net income (TTM)
−$386.97M
Trailing 12 months
Diluted EPS (TTM)
$-4.30
FCF margin
-471.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$73.50
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$7.09

Growth

11 metrics
Revenue growth YoY
+278.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$71.13M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+27.8%
Year over year · more shares
Revenue CAGR (3Y)
+241.9%
Revenue CAGR (5Y)
+132.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-58.4%
Return on assets
-35.3%
Debt / equity
0.5
Current ratio
16.9
EBITDA (TTM)
−$404.73M
Free cash flow (TTM)
−$335.04M
Quick ratio
—
Interest coverage
-25.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$190.81M
Latest balance sheet
Cash & equivalents
$164.99M
Total assets
$1.10B
Total debt
$355.80M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$333.34M
Capital expenditures (TTM)
$1.70M
R&D (TTM)
$324.68M
SG&A (TTM)
$151.65M
Stock compensation (TTM)
$53.61M
R&D / revenue
456.5%
Stock compensation / revenue
75.4%

Ownership (13F)

9 metrics
13F filers
217
13F filer change QoQ
-9
Institutional ownership
120.5%
Conviction holders (share of 13F filers)
3.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+24.1%
Holder tenure
12.3
Price vs estimated holder cost
-10.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.1%

Short interest

3 metrics
Short interest
15.9%
Latest settlement · 8.9 days to cover
Days to cover
8.9d
Short-squeeze score
89 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$348,194
Insider-sentiment score
44 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1590750 CUSIP 92790C104 13F (30d) 13 filings 13 filers Visit website Investor relations